# A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers

> **NCT05192395** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 37 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DWJ1525
- **DRUG:** DWP16001
- **DRUG:** DWC202101

## Key facts

- **NCT ID:** NCT05192395
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-15
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192395, "A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05192395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*